- Home
- LIXT vs TTNP Comparison
LIXT vs TTNP Comparison
Compare LIXT & TTNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- TTNP
- Stock Information
- Founded
- LIXT 2005
- TTNP 1991
- Country
- LIXT United States
- TTNP United States
- Employees
- LIXT N/A
- TTNP N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LIXT Health Care
- TTNP Health Care
- Exchange
- LIXT Nasdaq
- TTNP Nasdaq
- Market Cap
- LIXT 4.1M
- TTNP 3.4M
- IPO Year
- LIXT N/A
- TTNP 1996
- Fundamental
- Price
- LIXT $1.22
- TTNP $4.00
- Analyst Decision
- LIXT
- TTNP
- Analyst Count
- LIXT 0
- TTNP 0
- Target Price
- LIXT N/A
- TTNP N/A
- AVG Volume (30 Days)
- LIXT 31.7K
- TTNP 33.6K
- Earning Date
- LIXT 03-24-2025
- TTNP 05-14-2025
- Dividend Yield
- LIXT N/A
- TTNP N/A
- EPS Growth
- LIXT N/A
- TTNP N/A
- EPS
- LIXT N/A
- TTNP N/A
- Revenue
- LIXT N/A
- TTNP N/A
- Revenue This Year
- LIXT N/A
- TTNP N/A
- Revenue Next Year
- LIXT N/A
- TTNP N/A
- P/E Ratio
- LIXT N/A
- TTNP N/A
- Revenue Growth
- LIXT N/A
- TTNP N/A
- 52 Week Low
- LIXT $1.02
- TTNP $3.03
- 52 Week High
- LIXT $3.80
- TTNP $14.80
- Technical
- Relative Strength Index (RSI)
- LIXT 41.29
- TTNP 55.27
- Support Level
- LIXT $1.15
- TTNP $3.48
- Resistance Level
- LIXT $1.31
- TTNP $4.47
- Average True Range (ATR)
- LIXT 0.11
- TTNP 0.35
- MACD
- LIXT 0.03
- TTNP 0.01
- Stochastic Oscillator
- LIXT 43.24
- TTNP 56.07
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.